|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Yet patients with tumors lacking <i>BRCA</i> loss of heterozygosity (LOH) or lacking other evidence of probable loss of normal <i>BRCA</i> gene product expression might be less likely to benefit from PARP inhibitor therapy, because the efficacy of PARP inhibitor therapy in patients with germline <i>BRCA</i> mutations would likely be predicated upon <i>BRCA</i> LOH in their tumors.
|
29866945 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP.
|
18059167 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Western blot analysis demonstrated that the treatment of tumor cells with RGD-TRAIL activated the apoptotic pathway by the cleavage of PARP, in the same way as wild-type TRAIL (wtTRAIL).
|
22965279 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We show, for the first time, that IDO mediates human tumor cell resistance to a PARP inhibitor (olaparib), gamma radiation, cisplatin, and combined treatment with olaparib and radiation, in the absence of immune cells.
|
24784564 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We propose that combined blockade of ATR and PARP is an effective strategy for GBM, even for low-Myc GSCs that do not respond to PARPi alone, and potentially other PARPi-refractory tumors.
|
31266951 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We observed a positive association between the PARP codon 940 Lys/Arg and Arg/Arg genotypes and colorectal cancer risk [odds ratio (OR), 1.8; 95% confidence interval (95% CI), 1.1-3.1], and an inverse association between the MGMT codon 84 Leu/Phe or Phe/Phe genotypes and colon cancer risk (OR, 0.6; 95% CI, 0.3-0.9), but not rectal cancer (test of heterogeneity by tumor site, P=0.027).
|
18006925 |
2007 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified 8 patients and determined the impact of the specific DNA repair gene alterations on tumor response and time on treatment with PARP inhibition.
|
30099369 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that inhibition of PARP activity dramatically reduces tumor forming ability of HeLa cells.
|
10597301 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We describe a method that triggers susceptibility to PARP inhibition in BRCA1-functional tumor cells.
|
27997688 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We demonstrated that AdVING4/p53-mediated p53 and ING4 co-expression induced synergistic growth inhibition and apoptosis as well as enhanced effects on upregulation of acetylated p53, P21, Bax, PUMA, Noxa, cleaved caspase-9, cleaved caspase-3 and cleaved PARP, and downregulation of Bcl-2, CD31 and microvessel density (MVD) in MDA-MB-231 breast cancer in vitro and/or in vivo subcutaneous (s.c.) xenografted tumors.
|
26530780 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Various secondary endpoints are assessed: variations of different biomarkers at the tumour level (tissue microarrays to evaluate DNA-PKs, PARP, AR and splice variants, PSMA, etc.), whole transcriptome sequencing, exome sequencing and clinical (PSA and testosterone kinetics, early biochemical recurrence free survival, quality of life, safety, etc.) and radiological endpoints.
|
29606109 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of HN12 tumor bearing mice with i.p. or i.t. administration of IL-13 cytotoxin mediated marked regression of established tumors with complete remission.Interestingly, after a single i.t. administration, IL-13 cytotoxin disappeared within 6 hr but accumulation of caspase-3, -8 and -9 and cleavage of procaspase-3 and PARP continued within the tumors for a prolonged period.
|
12455052 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transplantable xenografts created from known BRCA1 germline mutation carriers were analyzed for histopathologic response (tumor volume, apoptotic and mitotic indices) to combination carboplatin/paclitaxel and to PARP inhibitor (PJ34).
|
18547621 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus MLN4924 may collaborate with PARP inhibitor to suppress tumor.
|
28034751 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This unusual DNA damage response may be a more appropriate strategy for an aggressive and rapidly growing tumour like melanoma that enables it to better survive chemotherapy, but also results in increased sensitivity of cultured melanoma cells to the PARP inhibitor olaparib.
|
29254481 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This survey reminds also that PARP inhibitors increase substantially the antitumor activity of TZC and can be administered with the intent of suppressing more efficiently tumor load and possibly reducing ITH through downsizing the polyclonality of xenogenized tumor cell population.
|
29530602 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These improvements open the possibility of BRCA1/2 testing for a wider spectrum of at-risk women, and will allow the genetic classification of tumors prior to the use of novel PARP inhibitors to treat BRCA-deficient breast cancers.
|
20127978 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings suggest a new therapeutic strategy for ATM-mutant CRPC patients by targeting LDHA-mediated glycolysis metabolism, which might be effective for the PARP inhibitor resistant mCRPC tumors.
|
30400006 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings have clinical significance, as the expression levels of p12 could be a predictive biomarker of tumor response to PARP inhibitors.
|
30470508 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The use of PARP inhibitors in combination with radiotherapy is a promising strategy to locally enhance DNA damage in tumors.
|
28500233 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The success of immune checkpoint inhibition in mismatch repair deficient tumors, PARP inhibitors for tumors with DNA repair defects, and targeting hyaluronan with PEGPH20 in patients with high expressing (hyaluronan-high) tumors are examples of promising biomarker-driven therapies.
|
30391013 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The role these genes play in DNA repair is thought to explain why tumors associated with them are sensitive to platin derivatives and PARP inhibitors.
|
21637635 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results revealed that tetrandrine exhibits significant antitumour activity against gastric human cancer cell and the antigastric tumour activity was depended on inducing autophagy and apoptosis through upregulating the apoptosis-related protein (cleaved PARP, cleaved caspase-3 and cleaved caspase-9) and autophagy-related protein (Beclin-1, LC3-II and p62), and decreasing the phosphorylation of AKT/mTOR, PS6K and P-4EBP1.
|
29770446 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents.
|
24798692 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study demonstrated that HARPΔ111-136 induced the ATF4/ATF3/CHOP cascade resulting in a strong expression of the proapoptotic protein CHOP, leading to tumor cell apoptosis as demonstrated by PARP cleavage and FACS analysis. siRNA-mediated CHOP gene silencing abolished Ad-HARPΔ111-136 induced apoptosis.
|
21109939 |
2011 |